BioTuesdays

Tag - ONTX

Onconova Logo
Markets

HCW cuts Onconova Therapeutics to neutral; removes PT

H.C. Wainwright downgraded Onconova Therapeutics (NASDAQ:ONTX) to “neutral” from “buy” without a price target after the company’s Phase 3 INSPIRE trial with rigosertib in high-risk myelodysplastic syndromesfailed on...

August 24, 2020
Onconova Logo
Markets

Maxim ups Onconova Therapeutics PT to $3 from $1.25

Maxim Group raised its price target for Onconova Therapeutics (NASDAQ:ONTX) to $3 from $1.25 after the company announced that the required number of survival events for the pivotal Phase 3 INSPIRE study of IV rigosertib...

July 30, 2020
Onconova Logo
Markets

Maxim ups Onconova Therapeutics to buy; PT $1.25

Maxim Group upgraded Onconova Therapeutics (NASDAQ:ONTX) to “buy” from “hold” with a new price target of $1.25, citing a strengthened balance sheet, and a sufficient cash runway into the third quarter of 2021, well past...

May 15, 2020
Onconova Logo
Markets

Noble starts Onconova Therapeutics at OP; PT $12

Noble Financial launched coverage of Onconova Therapeutics (NASDAQ:ONTX) with an “outperform” rating and $12 price target. The stock was quoted at $2.62 at midday on July 25. Onconova is currently focused on completing...

July 25, 2019